Related Experiment Video
Updated: Feb 25, 2026
09:14
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
2.9K
Drug therapy for chronic subdural hematoma: Bench to bedside
Shuanglin Fu1, Fubin Li2, Li Bie1
1Department of Neurosurgery of the First Clinical Hospital, Jilin University, Changchun, China.
Summary
Chronic subdural hematoma (CSDH) is an inflammatory disease. Understanding its molecular mechanisms and biomarkers may lead to new drug therapies, improving patient outcomes beyond current surgical interventions.
Area of Science:
- Neurosurgery
- Pathology
- Molecular Biology
Background:
- Chronic subdural hematoma (CSDH) is a prevalent neurosurgical condition.
- Current primary treatment relies on surgical intervention.
- CSDH involves complex inflammatory and angiogenic processes.
Purpose of the Study:
- To review recent advancements in understanding the molecular mechanisms of CSDH pathogenesis.
- To summarize findings from previous drug treatment studies for CSDH.
- To explore the potential of hematoma fluid and membrane characteristics as biomarkers.
Main Methods:
- Literature review of molecular mechanisms in CSDH.
- Analysis of past clinical studies on drug treatments for CSDH.
- Investigation of hematoma fluid and outer membrane properties as potential biomarkers.
Main Results:
- CSDH pathogenesis is driven by multifactorial inflammatory and angiogenic mechanisms.
- Hematoma fluid and outer membrane characteristics show potential as disease biomarkers.
- Biomarkers may synergistically contribute to CSDH initiation and progression.
Conclusions:
- Elucidating molecular pathways is crucial for advancing CSDH clinical management.
- Biomarker identification offers potential for novel therapeutic targets.
- Drug therapy targeting biomarkers could complement or improve upon surgical treatments for CSDH.
